Evidence map›Paper›PMID 37694246›Full record

ArticleAdvanced biomedical research2023

Evaluation of Expression Levels of NFATc2 and PPARG Genes Two Effector Elements of WNT Pathway in Non-Small Cell Lung Carcinoma.

Kaveh Motamediyan, Venus Zafari, Soghra Bornehdeli, Ayşe Caner, Milad Asadi, Shahryar Hashemzadeh, Mohammad Reza Firozi, Mortaza Raeisi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced biomedical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Kaveh MotamediyanTuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Venus ZafariDepartment of Basic Oncology of Health, Institute of Ege University, Izmir, Turkey.
Soghra BornehdeliTuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Ayşe CanerDepartment of Basic Oncology of Health, Institute of Ege University, Izmir, Turkey.
Milad AsadiDepartment of Basic Oncology of Health, Institute of Ege University, Izmir, Turkey.
Shahryar HashemzadehTuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mohammad Reza FiroziTuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mortaza RaeisiHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Tabriz University of Medical Sciences · IREge University · TRImam Reza Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There is an emergency need in discovering an efficient profile of molecular biomarkers for early diagnosis of Non-small cell lung cancer (NSCLC). Transcription factors as important groups of regulators that are able to adjust the cell cycles have attracted the attention of most researchers recently. NFATc2 and PPARG are two important factors that have been selected for this project to assess their potential for being a biomarker for NSCLC. Materials and Methods: Here in this study, 50 NSCLC patients were included. During bronchoscopy, which was their routine diagnostic approach, we collected tumoral and marginal normal tissues. After the extraction of the total RNA from the tissues, cDNA was synthesized, and the transcriptional level of NFATc2 and PPARG was examined by quantitative real-time PCR. Subsequently, the data were analyzed by proper statistical analyses. Results: The mRNA expression of NFATc2 and PPARG were down-regulated in biopsy tissues of NSCLC patients compared with their pair marginal tissues ( Conclusion: It appears that mRNA expression of NFATc2 and PPARG possesses the potential to be regarded as a diagnostic or prognostic biomarker for NSCLC.

Indexed as

BiomarkerNFATc2NSCLCPPARG

Identifiers

PMID37694246
PMCPMC10492599
OpenAlexW4385152929

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.